Ensysce Biosciences Secures Second Financing From 2025 Agreement to Advance Breakthrough Pain Programs
Rhea-AI Summary
Ensysce Biosciences (NASDAQ:ENSC) closed a second tranche of convertible preferred financing of $2.0 million on April 7, 2026, under a prior commitment providing up to $20 million over 24 months. The tranche has a $0.55 fixed conversion price and alternate conversion tied to average common prices.
The financing carries 100% warrant coverage with an 18-month term and an additional 100% warrant coverage with a five-year term, each exercisable at the fixed conversion price subject to adjustment. Proceeds will fund flagship abuse- and overdose-resistant analgesic programs and general corporate needs, alongside federal grant support for the MPAR program.
AI-generated analysis. Not financial advice.
Positive
- Closed $2.0M convertible preferred financing
- Commitment of up to $20M available over 24 months
- Fixed conversion price at $0.55 per share
- 100% warrant coverage with 18-month and 5-year terms
- Financing directed to flagship analgesic programs and corporate needs
Negative
- Potential shareholder dilution from conversion and warrant coverage at $0.55
- Immediate $2.0M tranche may be limited versus full program funding needs
News Market Reaction – ENSC
On the day this news was published, ENSC gained 3.04%, reflecting a moderate positive market reaction. Argus tracked a trough of -18.2% from its starting point during tracking. Our momentum scanner triggered 9 alerts that day, indicating moderate trading interest and price volatility. This price movement added approximately $158K to the company's valuation, bringing the market cap to $5.34M at that time.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Market Reality Check
Peers on Argus
ENSC is down 8.28% while momentum-screened peers like ARTL and SILO showed strong upside moves earlier, and same-day sector peers show a mix of gains and losses. This pattern points to stock-specific dynamics rather than a unified biotech move.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Mar 30 | Earnings and pipeline | Positive | +4.8% | Year-end 2025 results and PF614 Phase 3, PF614-MPAR progress update. |
| Mar 04 | Investor outreach AMA | Positive | -1.0% | Live AMA discussing PF614 growth plans and capital discipline. |
| Mar 03 | Clinical publication | Positive | -15.0% | Peer-reviewed Phase 1 data showing oral overdose protection for PF614-MPAR. |
| Feb 25 | Strategic review | Positive | +1.1% | Board launches review of strategic alternatives to enhance shareholder value. |
| Feb 23 | Conference participation | Positive | -6.6% | Announcements of multiple upcoming scientific and industry presentations. |
Recent history shows mixed reactions, with several positive clinical and strategic updates followed by negative price moves, suggesting the stock has often sold off or remained weak on good news.
Over the last few months, Ensysce has highlighted clinical and strategic progress, including initiation of the PF614 Phase 3 trial and continued PF614-MPAR development with FDA Breakthrough support (Mar 30, 2026). The company hosted an investor-focused AMA on Mar 4 and reported a positive Phase 1 MPAR publication on Mar 3. It also began reviewing strategic alternatives on Feb 25 and announced multiple conference appearances. Against this backdrop, today’s financing update extends a capital pathway supporting those same programs.
Market Pulse Summary
This announcement adds $2 million of convertible preferred financing from a larger $20 million commitment, supporting Ensysce’s late-stage pain programs and general operations. The structure includes a fixed $0.55 conversion price and layered warrant coverage, which can introduce dilution alongside balance sheet support. Recent history shows continued progression of PF614 and MPAR, a strategic review, and active investor outreach. Investors may watch execution on clinical milestones and any further capital draws under the agreement.
Key Terms
convertible preferred stock financial
conversion price financial
warrant coverage financial
warrants financial
AI-generated analysis. Not financial advice.
~Continued funding underscores investor confidence and supports advancement of abuse- and overdose-resistant analgesics~
SAN DIEGO, CA / ACCESS Newswire / April 7, 2026 / Ensysce Biosciences, Inc. (NASDAQ:ENSC) ("Ensysce" or the "Company"), pioneering novel solutions for severe pain with built-in abuse and overdose protection, today announced the closing of a second convertible preferred stock financing of
The capital will maintain Ensysce's flagship analgesic programs, while supporting general corporate initiatives. The current
Dr. Kirkpatrick, CEO of Ensysce Biosciences, stated, "This financing reflects continued investor confidence in Ensysce's differentiated analgesic programs, which we believe have the potential to reinvent pain management. Along with additional funds through our federal grant support for our MPAR program, we continue to advance the development of transformative treatments for patients in severe pain."
About Ensysce Biosciences
Ensysce Biosciences is a clinical stage company with a goal of disrupting the analgesic landscape by introducing a new class of highly novel opioids for the treatment of severe pain. Leveraging its Trypsin-Activated Abuse Protection (TAAPTM) and Multi-Pill Abuse Resistance (MPAR®) platforms, the Company is developing unique, tamper-proof treatment options for pain that minimize the risk of both drug abuse and overdose. Ensysce's products are anticipated to provide safer options to treat patients suffering from severe pain and assist in preventing deaths caused by medication abuse. Ensysce's pipeline is backed by a robust global intellectual property portfolio, offering hope to patients and providers confronting the challenges of pain management. Learn more at www.ensysce.com.
Forward-Looking Statements
Statements contained in this press release that are not purely historical may be deemed to be forward-looking statements for the purposes of the safe harbor provisions under The Private Securities Litigation Reform Act of 1995 and other federal securities laws. Without limiting the foregoing, the use of words such as "may," "intends," "can," "might," "will," "expect," "plan," "possible," "believe" and other similar expressions are intended to identify forward-looking statements. The product candidates discussed are in clinic and not approved and there can be no assurance that the clinical programs will be successful in demonstrating safety and/or efficacy, that Ensysce will not encounter problems or delays in clinical development, or that any product candidate will ever receive regulatory approval or be successfully commercialized. All forward-looking statements are based on estimates and assumptions by Ensysce's management that, although Ensysce believes to be reasonable, are inherently uncertain. All forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially from those that Ensysce expected. In addition, Ensysce's business is subject to additional risks and uncertainties, including among others, the initiation and conduct of preclinical studies and clinical trials; the timing and availability of data from preclinical studies and clinical trials; expectations for regulatory submissions and approvals; potential safety concerns related to, or efficacy of, Ensysce's product candidates; the availability or commercial potential of product candidates; the ability of Ensysce to fund its continued operations, including its planned clinical trials; the dilutive effect of stock issuances from our fundraising; and Ensysce's and its partners' ability to perform under their license, collaboration and manufacturing arrangements. These statements are also subject to a number of material risks and uncertainties that are described in Ensysce's most recent annual report on Form 10-K and current reports on Form 8-K, available free of charge at the SEC's website at www.sec.gov. Any forward-looking statement speaks only as of the date on which it was made. Ensysce undertakes no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events or otherwise, except as required under applicable law.
Ensysce Biosciences Company Contact:
Lynn Kirkpatrick, Ph.D.
Chief Executive Officer
(858) 263-4196
Ensysce Biosciences Investor Relations Contact:
Shannon Devine
MZ North America
Main: 203-741-8811
ENSC@mzgroup.us
SOURCE: Ensysce Biosciences Inc.
View the original press release on ACCESS Newswire